RRMM definition is based on the recommendation of International Myeloma Working Group (IMWG), as the disease recurs after the initial response and manifests as the development of new plasmacytomas or hypercalcemia, ≥25% increase of the urine or serum monoclonal protein (M-protein), or the development of new hypercalcemia or plasmacytomas [10]. The gene discussed is MYOM2; the disease is plasmacytoma.